TruScreen Group Limited — Capital/Financing Update 2020

Jun 4, 2020

==> picture [261 x 38] intentionally omitted <==

NZX Announcement

4 June 2020

Truscreen Limited priority allocation of $1 million closed

Truscreen is pleased to announce that its previously announced offer to raise $1,000,000 through a priority allocation to an NZX market participant closed on 3 June 2020, fully subscribed.

TRU expects that the new shares to be issued pursuant to the priority allocation will be allotted, and holder statements sent out to shareholders on or about Friday 5 June 2020.

Auckland based capital markets advisory firm CM Partners advised TRU on the capital raising initiative.

• ENDS -

For more information, visit www.truscreen.com or contact:

TruScreen

Victoria Potarina Guy Robertson Chief Executive Officer Chief Financial Officer victoriapotarina@truscreen.com guyrobertson@truscreen.com

==> picture [261 x 38] intentionally omitted <==

About TruScreen:

TruScreen is a Cervical Cancer Screening Device which offers the latest technology in cervical screening, providing real-time, accurate detection of precancerous and cancerous cervical cells to help improve the health and well-being of women around the world. TruScreen’s real-time cervical cancer technology utilises a digital wand which is placed on the surface of the cervix to measure electrical and optical signals from the surrounding tissues. A sophisticated proprietary algorithm framework is utilised to detect pre-cancerous change, or cervical intra-epithelial neoplasia (CIN), by optical and electrical measurement of cervical tissue.

==> picture [186 x 83] intentionally omitted <==

==> picture [173 x 58] intentionally omitted <==

TruScreen offers an alternative approach to cervical screening, resolving many of the ongoing issues with Pap tests, including failed samples, poor patient follow-up, patient discomfort and the need for supporting laboratory infrastructures. As such, TruScreen’s target market is lowand middle-income countries where no large-scale cervical cancer screening programs and infrastructure are in place, such as China, Mexico, Africa, Russia and India. TruScreen’s cervical cancer screening device is CE-marked and certified for use throughout Europe and CFDAapproved for sale in China. The global market potential for TruScreen is significant.

For more information, visit our website at www.truscreen.com

Watch our video on TruScreen: http://truscreen.com/truscreen-the-company/truscreen- ultravideo/